Prosecution Insights
Last updated: November 04, 2026
Application No. 19/001,571

THREE-DIMENSIONAL NETWORK AQUEOUS GEL AND MANUFACTURING METHOD THEREOF

Non-Final OA §103
Filed
Dec 26, 2024
Priority
Jan 11, 2022 — TW 111101154 +1 more
Examiner
WERTZ, ASHLEE ELIZABETH
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Nai-Wen Mei
OA Round
1 (Non-Final)
49%
Grant Probability
Moderate
1-2
OA Rounds
1y 7m
Est. Remaining
89%
With Interview

Examiner Intelligence

Grants 49% of resolved cases
49%
Career Allowance Rate
28 granted / 57 resolved
-10.9% vs TC avg
Strong +40% interview lift
Without
With
+40.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
51 currently pending
Career history
113
Total Applications
across all art units

Statute-Specific Performance

§101
0.6%
-39.4% vs TC avg
§103
49.8%
+9.8% vs TC avg
§102
7.1%
-32.9% vs TC avg
§112
17.7%
-22.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 57 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Priority This application filed on 12/26/2024 is a DIV of 18/095,538 filed on 01/11/2023 which claims foreign priority to TW 111101154 filed on 01/11/2022. The foreign priority application recites the manufacturing method as recited in claim 1 [0023], with the claimed polymers (claims 2-3) in the claimed amounts (claim 4) [0009], and the claimed pore size (claim 5) [0010]. Therefore, all claims of the instant invention have benefit to the priority date of 01/11/2022. Claim Objections Claim 1 is objected to because of the following informality. Claim 1 requires the degrees in line 16 to be defined (e.g., °C). Appropriate correction is required. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-4 are rejected under 35 U.S.C. 103 as being as being obvious over Perkasa et al. (Indones. J. Chem., 2018, 18 (2), 367 - 375) in view of Wang et al. (CN 1616116 A) and Sultana et al. (Journal of Bangladesh Chemical Society, Vol. 25(2), 132-138, 2012). Examiner’s Note: The size of the “nanometer-scale water-soluble polymer particles” is not defined in the claim nor explicitly defined in the instant specification. Therefore, any size of particles that is close to “nanometer” size (i.e., fractions of nanometers to hundreds of nanometers) reads on the claimed particles. Additionally, the term “degrees” in line 16 of claim 1 does not have units. The Examiner is interpreting “degrees” to be degrees Celsius as it is the unit used throughout the specification (e.g., Table 1) (however, appropriate correction/clarification is required as discussed above). Regarding claim 1, Perkasa discloses a preparation method for an aqueous, sodium alginate hydrogel material (abstract; pg. 369, left column) including adding the water-soluble polymer (“sodium alginate”) into a solvent (“water”) and uniformly mixing to form a homogeneous solution (“under continuous stirring”); subjecting the polymer to a hydrolysis reaction to form a sol (discloses the polymer is added into water and generates a “sol phase”); under a pressure of “200 mbar vacuum” (which is about 150 torr), subjecting the sol to vacuum conversion into a gel (“vacuum at ambient temperature overnight”); subjecting the gel to a polycondensation reaction to have the polymer particles and the solvent interconnected to form a three-dimensional network structure (“at sol phase, each of molded solution was overlaid with a 25 mL of 1.0% (w/v) CaCl2 solution for 2 h to allow for crosslinking”); and forming a three-dimensional network aqueous gel (“hydrogels were formed”) (pg. 369, left column). Perkasa teaches that the hydrogel is used as a wound dressing (abstract; pg. 367). Regarding the claimed pressure (25-760 torr), in the case where the claimed ranges “overlap or lie inside ranges disclosed by the prior art” a prima facie case of obviousness exists. See MPEP 2144.05 A. Regarding the limitation of “generating nanometer-scale water soluble polymer particles”, while Perkasa does not disclose the size of the polymer particles, the polymer particles are reasonably expected to be “nanometer-scale” as the claim is interpreted, as discussed above, as Perkasa discloses polymer particles and a sol phase (pg. 369, left column). Perkasa does not disclose that the gel includes sodium carboxymethyl cellulose or that the three-dimensional network aqueous gel is subjected to vacuum; wherein a temperature of the gel is controlled to be between 30-70 degrees and a pressure is controlled to be between 50-70 millimeters of mercury to control a degree of swelling of the gel and a structure of the gel. Wang teaches a gel wound dressing with a radiation sensitive agent such as sodium carboxymethyl cellulose (English translation, pg. 2, Example 1; claims 1-2). Wang teaches that the radiation sensitive agents have good biocompatibility, do not produce harmful effects, promote wound healing, and have antibacterial action (pg. 2, 5th paragraph from bottom). Since Perkasa generally teaches a hydrogel for wound healing, it would have been prima facie obvious to include sodium carboxymethyl cellulose, within the teachings of Perkasa because Wang teaches a hydrogel for wound healing with sodium carboxymethyl cellulose as a radiation sensitive agent. An ordinarily skilled artisan would have been motivated to use sodium carboxymethyl cellulose because Wang teaches that the radiation sensitive agents have good biocompatibility, do not produce harmful effects, promote wound healing, and have antibacterial action (pg. 2, 5th paragraph from bottom). The combined teachings of Perkasa and Wang do not disclose that the three-dimensional network aqueous gel is subjected to vacuum wherein a temperature of the gel is controlled to be between 30-70 degrees, and a pressure is controlled to be between 50-70 millimeters of mercury to control a degree of swelling of the gel and a structure of the gel. Sultana discloses carboxymethyl cellulose hydrogels where the hydrogels are dried in a vacuum oven at 50°C. Sultana teaches that the vacuum oven dries the hydrogels to obtain a constant weight (pg. 133, third paragraph from bottom). Since the combined teachings of Perkasa and Wang generally teaches a polymer hydrogel one of ordinary skill in the art would be motivated to vacuum the gel at 50°C in order to dry the hydrogel and obtain a constant weight as taught by Sultana (pg. 133, third paragraph from bottom). A prima facie case of obviousness exists because of overlap, as previously discussed. As Sultana teaches that the vacuum drying allows for a constat weight to be obtained, the vacuum drying at 50°C would be reasonably expected to “control a degree of swelling of the gel and a structure of the gel” as claimed. Regarding the claimed pressure, while Sultana does not state that the pressure is controlled to be between 50-70 mmHg, where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation. See MPEP 2144.05.II. Sultana teaches that the vacuum oven is used to dry the hydrogel to obtain a constant weight (pg. 133, third paragraph from bottom), it would not have been inventive for the skilled artisan to have optimized the pressure to dry the gel and/or obtain a constant weight. Regarding claim 2, it would have been obvious to include sodium carboxymethyl cellulose as taught by Wang, within the teachings of Perkasa, as previously discussed. The components of the gel (sodium carboxymethyl cellulose, sodium alginate, water) would be interconnected to form a three-dimensional network structure as Perkasa teaches that the process results in crosslinking and that hydrogels are formed (pg. 369, left column). Regarding claim 3, Perkasa does not disclose that the hydrogel further comprises polyvinylpyrrolidone. Wang discloses that the hydrogel for wound healing includes polyvinylpyrrolidone (abstract; claim 1). Wang teaches that the hydrogel with polyvinyl pyrrolidone is useful in protecting and treating wounds (abstract). Since Perkasa generally teaches a hydrogel for wound healing, it would have been prima facie obvious to include polyvinyl pyrrolidone, within the teachings of Perkasa because Wang teaches a hydrogel for wound healing with polyvinyl pyrrolidone. An ordinarily skilled artisan would have been motivated to use polyvinyl pyrrolidone because Wang teaches that the hydrogel with polyvinyl pyrrolidone is useful in protecting and treating wounds (abstract). The components of the gel (sodium carboxymethyl cellulose, sodium alginate, polyvinyl pyrrolidone, water) would be interconnected to form a three-dimensional network structure as Perkasa teaches that the process results in crosslinking and that hydrogels are formed (pg. 369, left column). Regarding claim 4, Perkasa does not disclose the claimed amount of sodium alginate, polyvinylpyrrolidone, and sodium carboxymethyl cellulose. However, Wang discloses that the hydrogel for wound healing has 1-30 mass % of polyvinyl pyrrolidone and 1-10 mass % of radiation sensitive agent, where the radiation sensitive agent is one or more materials such sodium carboxymethyl cellulose and sodium alginate (English translation, pg. 2, Example 1; claims 1-2). Wang teaches that the hydrogel with the combination of polyvinyl pyrrolidone and radiation sensitive agent(s) is useful in protecting and treating wounds (abstract; claims 1-2). Wang also teaches that the radiation sensitive agents promote wound healing and have antibacterial action (pg. 2, 5th paragraph from bottom; claims 1-2). It would have been prima facie obvious to include polyvinyl pyrrolidone in the amount taught by Wang (1-30 mass %), within the teachings of Perkasa because Wang teaches that hydrogels with this amount of polyvinyl pyrrolidone are useful in protecting and treating wounds (abstract; claims 1-2). Additionally, it would have been prima facie obvious to include sodium carboxymethyl cellulose and sodium alginate in the amount taught by Wang (1-10 mass %), within the teachings of Perkasa because Wang teaches that this amount of radiation sensitive agent(s) promotes wound healing and has antibacterial action (pg. 2, 5th paragraph from bottom; claims 1-2). In the case where the claimed ranges “overlap or lie inside ranges disclosed by the prior art” a prima facie case of obviousness exists. Furthermore, where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation. See MPEP 2144.05(II)(A). In this case, the general condition of hydrogels with sodium carboxymethyl cellulose, polyvinyl pyrrolidone, and sodium alginate have been taught by the prior art (Wang); as such, it would not have been inventive for the skilled artisan to have discovered the optimum amount of these components via routine experimentation to achieve the desired results (i.e., protecting and treating wounds, antibacterial action) within the combined teachings of the prior art. Claim 5 is rejected under 35 U.S.C. 103 as being as being obvious over Perkasa et al. (Indones. J. Chem., 2018, 18 (2), 367 - 375) in view of Wang et al. (CN 1616116 A) and Sultana et al. (Journal of Bangladesh Chemical Society, Vol. 25(2), 132-138, 2012) and further in view of Park et al. (US 6,271,278 B1). The 35 U.S.C. 103 rejection over Perkasa in view of Wang and Sultana was previously discussed. Regarding claim 5, the combined teachings of the prior art do not disclose a plurality of gel pores with a diameter of 16-18 µm. Park discloses a hydrogel containing crosslinked polymers such as polyvinylpyrrolidone, sodium carboxymethylcellulose, and sodium alginate (abstract; Col 6, line 58) where the gel has a pore size in the range of 10 µm to 3,000 µm (abstract). Park teaches that pores in the superporous hydrogels remain connected even after drying, which enables the dried hydrogels to swell extremely fast, thereby enabling high absorbency characteristics as well as high mechanical strength (Col 4, lines 40-43; lines 53-61). Since the combined teachings of the prior art generally teach polymer hydrogels it would have been prima facie obvious to a person having ordinary skill in the art to include pores which have a pore size in the range of 10 µm to 3,000 µm, as taught by Park, within the teachings of the prior art, because Park teaches that pores of this size enable the hydrogels to swell extremely fast, resulting in high absorbency and high mechanical strength of the hydrogel (Col 4, lines 40-43; lines 53-61). Regarding the pore size, a prima facie case of obviousness exists because of overlap, as previously discussed. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ashlee E Wertz whose telephone number is (571)270-7663. The examiner can normally be reached Monday - Friday, 8 AM - 5 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana Kaup can be reached at 571-272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ASHLEE E WERTZ/Examiner, Art Unit 1612 /SAHANA S KAUP/Supervisory Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Dec 26, 2024
Application Filed
Sep 21, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778863
TOPICAL SKIN PREPARATION COMPOSITION
4y 1m to grant Granted Nov 03, 2026
Patent 12772981
WATER-BASED INSECTICIDAL AND INSECT REPELLENT COMPOSITIONS
3y 11m to grant Granted Oct 27, 2026
Patent 12758479
ADHESIVE PHOTOPROTECTIVE COMPOUNDS AND USES THEREOF
4y 4m to grant Granted Oct 13, 2026
Patent 12708618
PHARMACEUTICAL COMPOSITE FORMULATION COMPRISING PROTON PUMP INHIBITOR AND ANTACID, AND METHOD FOR PREPARING SAME
3y 7m to grant Granted Aug 18, 2026
Patent 12702632
PROTEASE FORMULATION FOR TREATMENT OF MICROBIAL INFECTIONS
3y 9m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
49%
Grant Probability
89%
With Interview (+40.0%)
3y 5m (~1y 7m remaining)
Median Time to Grant
Low
PTA Risk
Based on 57 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month